We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onconova Therapeutics Inc | NASDAQ:ONTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.9953 | 1.00 | 1.05 | 0 | 01:00:00 |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(1)
|
| | | $ | | | | | $ | | | ||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | |
| | | | | S-ii | | | |
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-4 | | | |
| | | | | S-5 | | | |
| | | | | S-6 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-16 | | | |
| | | | | S-16 | | | |
| | | | | S-16 | | | |
| | | | | S-16 | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 15 | | |
|
Offering price per share in this offering
|
| | | | | | | | | $ | | | |
|
Net tangible book deficit per share as of June 30, 2021
|
| | | $ | 2.09 | | | | | | | | |
|
Increase in net tangible book value per share attributable to purchasers in this
offering |
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share immediately after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to purchasers in this offering
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number
of Shares |
| |||
Guggenheim Securities, LLC
|
| | | | | | |
Total
|
| | | | | | |
| | |
Per Share
|
| |
Total
|
| ||||||||||||
|
No
Exercise |
| |
Full
Exercise |
| ||||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions to be paid by us
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 15 | | |
of Selling Stockholder
|
| |
Number of
Shares Beneficially Owned Prior to the Offering |
| |
Number of
Shares Offered |
| |
Number of
Shares Beneficially Owned After the Offering |
| |
% of Common
Stock Beneficially Owned After the Offering |
| ||||||||||||
DKG Leasing-2000 LLC
|
| | | | 8 | | | | | | 8 | | | | | | 0 | | | | | | 0 | | |
Kathryn Jane McDonald
|
| | | | 2 | | | | | | 2 | | | | | | 0 | | | | | | 0 | | |
Utkarsh Palnitkar
|
| | | | 103 | | | | | | 103 | | | | | | 0 | | | | | | 0 | | |
1 Year Onconova Therapeutics Chart |
1 Month Onconova Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions